Results 21 to 30 of about 136,204 (260)

Selective activation of NFAT by promyelocytic leukemia protein [PDF]

open access: yesOncogene, 2008
Promyelocytic leukemia (PML) protein is a tumor suppressor with complicated action mechanisms not yet fully understood. In this study, we found that the nuclear factor of activated T cell (NFAT) is an unexpected partner of PML: PML specifically enhanced the transcription activation of NFAT.
Y-H, Lo, C-C, Wu, H-M, Shih, M-Z, Lai
openaire   +2 more sources

Biomolecular Condensates in Myeloid Leukemia: What Do They Tell Us?

open access: yesHemaSphere, 2023
Recent studies have suggested that several oncogenic and tumor-suppressive proteins carry out their functions in the context of specific membrane-less cellular compartments.
Zivojin Jevtic   +3 more
doaj   +1 more source

Case Report: Identification of a novel LYN::LINC01900 transcript with promyelocytic phenotype and TP53 mutation in acute myeloid leukemia

open access: yesFrontiers in Oncology, 2023
Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem/progenitor cells characterized by the abnormal proliferation of primitive and naive random cells in the bone marrow and peripheral blood. Acute promyelocytic leukemia (APL)
Chengjun Hu   +9 more
doaj   +1 more source

Effects of Promyelocytic Leukemia Protein on Virus-Host Balance [PDF]

open access: yesJournal of Virology, 2002
ABSTRACTThe cellular promyelocytic leukemia protein (PML) associates with the proteins of several viruses and in some cases reduces viral propagation in cell culture. To examine the role of PML in vivo, we compared immune responses and virus loads of PML-deficient and control mice infected with lymphocytic choriomeningitis virus (LCMV) and vesicular ...
Bonilla, Weldy V.   +8 more
openaire   +3 more sources

The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions

open access: yesFrontiers in Oncology, 2023
The transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL
S. Iyer   +3 more
semanticscholar   +1 more source

The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated

open access: yesHaematologica, 2011
Impairment of CCAAT Enhancer Binding Protein alpha (CEBPA) function is a common finding in acute myeloid leukemia; nevertheless, its relevance for acute promyelocytic leukemia pathogenesis is unclear.
Bárbara Amélia Santana-Lemos   +7 more
doaj   +1 more source

A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion [PDF]

open access: yes, 2018
Key Points Novel RARG-CPSF6 fusion in an AML case with promyelocytic features and no evidence of PML-RARA or X-RARA fusion. Gene fusions involving RARG can initiate AML with promyelocytic morphological features.
Duncavage, Eric J.   +13 more
core   +2 more sources

Regulation of NF-κB by PML and PML-RARα [PDF]

open access: yes, 2017
Promyelocytic Leukemia (PML) is a nuclear protein that forms sub-nuclear structures termed nuclear bodies associated with transcriptionally active genomic regions. PML is a tumour suppressor and regulator of cell differentiation.
Ahmed, Abrar   +8 more
core   +1 more source

The promyelocytic leukemia protein stimulates SUMO conjugation in yeast [PDF]

open access: yesOncogene, 2006
The promyelocytic leukemia gene was first identified through its fusion to the gene encoding the retinoic acid receptor alpha (RARalpha) in acute promyelocytic leukemia (APL) patients. The promyelocytic leukemia gene product (PML) becomes conjugated in vivo to the small ubiquitin-like protein SUMO-1, altering its behavior and capacity to recruit other ...
B B, Quimby   +4 more
openaire   +2 more sources

Cellulitis with Leukocytopenia as an Initial Sign of Acute Promyelocytic Leukemia

open access: yesCase Reports in Dermatology, 2012
Patients with hematologic malignancies are immunosuppressive and may develop cutaneous or invasive infections as a primary sign of immune suppression.
Sachiko Sakamoto   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy